Eric Mick to Treatment Outcome
This is a "connection" page, showing publications Eric Mick has written about Treatment Outcome.
Connection Strength
0.082
-
McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, Luzuriaga K. Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS One. 2016; 11(4):e0154391.
Score: 0.015
-
Johnson E, Chase K, McGowan S, Mondo E, Pfister E, Mick E, Friedline RH, Kim JK, Sapp E, DiFiglia M, Aronin N. Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model. J Huntingtons Dis. 2015; 4(3):219-229.
Score: 0.014
-
Maloney A, Mick EO, Frazier J. Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2014 Aug; 24(6):357-9.
Score: 0.013
-
Shaikh AY, Maan A, Khan UA, Aurigemma GP, Hill JC, Kane JL, Tighe DA, Mick E, McManus DD. Speckle echocardiographic left atrial strain and stiffness index as predictors of maintenance of sinus rhythm after cardioversion for atrial fibrillation: a prospective study. Cardiovasc Ultrasound. 2012 Dec 03; 10:48.
Score: 0.012
-
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010 Oct; 30(5):549-53.
Score: 0.010
-
Polanczyk G, Faraone SV, Bau CH, Victor MM, Becker K, Pelz R, Buitelaar JK, Franke B, Kooij S, van der Meulen E, Cheon KA, Mick E, Purper-Ouakil D, Gorwood P, Stein MA, Cook EH, Rohde LA. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 05; 147B(8):1419-24.
Score: 0.009
-
Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Mar 01; 57(5):456-63.
Score: 0.007